- Home
- NUVL vs AMKR Comparison
NUVL vs AMKR Comparison
Compare NUVL & AMKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- AMKR
- Stock Information
- Founded
- NUVL 2017
- AMKR 1968
- Country
- NUVL United States
- AMKR United States
- Employees
- NUVL N/A
- AMKR N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- AMKR Semiconductors
- Sector
- NUVL Health Care
- AMKR Technology
- Exchange
- NUVL Nasdaq
- AMKR Nasdaq
- Market Cap
- NUVL 5.6B
- AMKR 6.1B
- IPO Year
- NUVL 2021
- AMKR 1998
- Fundamental
- Price
- NUVL $74.61
- AMKR $18.02
- Analyst Decision
- NUVL Strong Buy
- AMKR Buy
- Analyst Count
- NUVL 8
- AMKR 7
- Target Price
- NUVL $115.50
- AMKR $26.67
- AVG Volume (30 Days)
- NUVL 548.5K
- AMKR 1.8M
- Earning Date
- NUVL 05-08-2025
- AMKR 04-28-2025
- Dividend Yield
- NUVL N/A
- AMKR 4.06%
- EPS Growth
- NUVL N/A
- AMKR N/A
- EPS
- NUVL N/A
- AMKR 1.28
- Revenue
- NUVL N/A
- AMKR $6,273,756,000.00
- Revenue This Year
- NUVL N/A
- AMKR $1.79
- Revenue Next Year
- NUVL N/A
- AMKR $6.24
- P/E Ratio
- NUVL N/A
- AMKR $14.08
- Revenue Growth
- NUVL N/A
- AMKR N/A
- 52 Week Low
- NUVL $55.54
- AMKR $14.03
- 52 Week High
- NUVL $113.51
- AMKR $44.86
- Technical
- Relative Strength Index (RSI)
- NUVL 54.31
- AMKR 45.84
- Support Level
- NUVL $70.25
- AMKR $17.97
- Resistance Level
- NUVL $75.97
- AMKR $18.94
- Average True Range (ATR)
- NUVL 3.09
- AMKR 0.51
- MACD
- NUVL 0.13
- AMKR -0.13
- Stochastic Oscillator
- NUVL 79.92
- AMKR 9.24
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About AMKR Amkor Technology Inc.
Amkor Technology Inc is a provider of outsourced semiconductor packaging and test services to integrated device manufacturers, fabless semiconductor companies, and contract foundries. The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.